Editorial Board

• Francisco M. Averhoff, Centers for Disease Control and Prevention, USA
• Jim P. Buttery, The Murdoch Childrens Research Institute, Australia
• William C. S. Cho, Queen Elizabeth Hospital, Hong Kong
• Myron Christodoulides, University of Southampton, United Kingdom
• Rhea Coler, Infectious Disease Research Institute, USA
• Guido Dietrich, GlaxoSmithKline Biologicals, Belgium
• Isabelle Dimier-Poisson, Université François Rabelais - Tours, France
• Jean-Louis Excler, International AIDS Vaccine Initiative, Switzerland
• Germain J. Fernando, University of Queensland, Australia
• Elisabetta Franco, Università Tor Vergata, Italy
• Tong-Ming Fu, Merck Research Laboratories, USA
• Ivaylo Gentschev, University of Wuerzburg, Germany
• Magdalena Gherardi, Universidad de Buenos Aires, Argentina
• Mark Grabowsky, Global Fund for AIDS, TB and Malaria, Switzerland
• Gerardo E. Guillén Nieto, Centro de Ingeniería Genética y Biotecnológica, Cuba
• Joel R. Haynes, LigoCyte Pharmaceuticals, Inc., USA
• John Iskander, Centers for Disease Control and Prevention, USA
• Helena Käyhty, National Institute for Health and Welfare (THL), Finland
• Gideon Kersten, Netherlands Vaccine Institute, The Netherlands
• Katrin S. Kohl, Centers for Disease Control and Prevention, USA
• James P. McGettigan, Thomas Jefferson University, USA
• Sergio Costa Oliveira, Universidade Federal de Minas Gerais, Brazil
• Ultan Power, Queen's University Belfast, United Kingdom
• David Russell, University of Oslo, Norway
• Masaru Shimada, Yokohama City University, Japan
• Jim Tartaglia, Sanofi Pasteur, Canada
• Michael Vajdy, Epitogenesis, Inc., USA
• Ramesh Vemulapalli, Purdue University, USA
• Michael Wallach, University of Technology, Sydney, Australia
• Shixia Wang, University of Massachusetts Medical School, USA
• Andrés Wigdorovitz, INTA - Instituto de Virología, Argentina
• Diane Williamson, Defence Science and Technology Laboratory, United Kingdom
• Lijuan Yuan, Virginia Polytechnic Institute and State University, USA